CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy

Author:

Xu Jiabin12345,Liu Hong6,Wang Tao123,Wen Zhenfu6,Chen Haolin6,Yang Zeyu6,Li Liyan6,Yu Shan123,Gao Siyong123,Yang Le123,Li Kan123,Li Jingyuan123,Li Xiang123,Liu Lixin6,Liao Guiqing123,Chen Yongming6,Liang Yujie123ORCID

Affiliation:

1. Hospital of Stomatology Sun Yat‐sen University Guangzhou 510030 P. R. China

2. Guangdong Provincial Key Laboratory of Stomatology Guangzhou 510030 P. R. China

3. Institute of Stomatology Sun Yat‐sen University Guangzhou 510030 P. R. China

4. School of Stomatology Xuzhou Medical University Xuzhou 221004 P. R. China

5. Affiliated Stomatological Hospital of Xuzhou Medical University Xuzhou 221004 P. R. China

6. School of Materials Science and Engineering Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education Sun Yat‐sen University Guangzhou 510275 P. R. China

Abstract

AbstractImmunotherapy has been recognized as one of the most promising treatment strategies for head and neck squamous cell carcinoma (HNSCC). As a pioneering trend of immunotherapy, dendritic cell (DC) vaccines have displayed the ability to prime an immune response, while the insufficient immunogenicity and low lymph node (LN) targeting efficiency, resulted in an unsubstantiated therapeutic efficacy in clinical trials. Herein, a hybrid nanovaccine (Hy‐M‐Exo) is developed via fusing tumor‐derived exosome (TEX) and dendritic cell membrane vesicle (DCMV). The hybrid nanovaccine inherited the key protein for lymphatic homing, CCR7, from DCMV and demonstrated an enhanced efficiency of LN targeting. Meanwhile, the reserved tumor antigens and endogenous danger signals in the hybrid nanovaccine activated antigen presenting cells (APCs) elicited a robust T‐cell response. Moreover, the nanovaccine Hy‐M‐Exo displayed good therapeutic efficacy in a mouse model of HNSCC. These results indicated that Hy‐M‐Exo is of high clinical value to serve as a feasible strategy for antitumor immunotherapy.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3